A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/17 (2006.01) A61K 38/19 (2006.01) A61K 48/00 (2006.01) A61P 37/02 (2006.01) C07K 14/47 (2006.01) C07K 14/52 (2006.01) C07K 16/24 (2006.01) C12N 5/10 (2006.01) C12N 15/12 (2006.01) G01N 33/50 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2370129
The present invention features new approaches for modulating immune responses. In particular, the invention features methods for modulating type 1 immune responses in a subject using modulators of Eta-1(early T lymphocyte activation- 1)/osteopontin. Examplary methods feature methods of treating infections, immune disorders and diseases, autoimmune disorders and diseases, various immunodeficiencies and cancer. Also provided are biosynthetic immunomodulatory molecules that include functional domains derived from Eta-1/osteopontin. Preferred biosynthetic immunomodulatory molecules include an IL-12 stimulatory domain derived from Eta-1/osteopontin or an IL-10 inhibitory domain derived from Eta-1/osteopontin. The immunomodulatory molecules of the present invention are capable of biasing an immune response in a subject towards a type 1 immune response. Accordingly, therapeutic uses are disclosed which are based on the biosynthetic immunomodulatory molecules of the present invention.
L'invention concerne de nouvelles approches pour la modulation de réponses immunitaires. L'invention concerne notamment des procédés de modulation de réponses immunitaires de type 1 chez un individu, à l'aide de modulateurs d'Eta-1 (activation précoce de lymphocyte T-1)/ostéopontine. A titre d'exemple, on peut citer des procédés portant sur des techniques de traitement d'infections, de troubles et maladies immunitaires, de troubles et maladies auto-immuns, de plusieurs immunodéficiences et du cancer. L'invention porte également sur des molécules biosynthétiques immunomodulatrices comprenant des domaines fonctionnels dérivés de l'Eta-1/ ostéopontine. Des molécules biosynthétiques immunomodulatrices comprennent un domaine stimulateur d'IL-12, dérivé de l'Eta-1/ ostéopontine ou un domaine inhibiteur d'IL-10, dérivé de l'Eta-1/ ostéopontine. Les molécules immunomodulatrices de l'invention peuvent, chez un sujet, faire pencher une réponse immunitaire vers une réponse immunitaire de type 1. Des utilisation thérapeutiques correspondantes, fondées sur les molécules biosynthétiques immunomodulatrices de l'invention, sont également décrites.
Ashkar Samy
Cantor Harvey
Glimcher Melvyn
Weber Georg
Children's Medical Center Corporation
Dana-Farber Cancer Institute Inc.
Gowling Lafleur Henderson Llp
LandOfFree
Methods and compositions for modulating an immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating an immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating an immune response will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1764464